This filing is purely administrative — a segment recast with no new financial information or corporate events. There is no trading signal. Monitor the next quarterly report for organic growth trends in the new Ortho Tech business and any impact on segment margin trajectory.
Price Chart
Executive Summary
Stryker filed an 8-K to recast historical segment financials for 2023-2025 following a Q1 2026 organizational restructuring that created a new Ortho Tech business (combining orthopaedic instruments with Mako/enabling technologies). This is a routine accounting change to conform prior-period segment data to the new reporting structure — it does not restate or amend the audited consolidated financial statements and contains no new financial results, guidance, or material events.
Key Facts
- Stryker reorganized in Q1 2026, creating a new Ortho Tech business within the Orthopaedics segment by combining orthopaedic instruments from Instruments with Mako and enabling technologies from Other Orthopaedics.
- The two reportable segments remain MedSurg and Neurotechnology and Orthopaedics.
- Historical segment financials for 2023-2025 have been recast to reflect the new structure; consolidated results are unchanged.
- The filing includes recast MD&A, financial statements, and notes from the 2025 10-K, plus an auditor consent (Exhibit 23.1).
- The recast does not amend or restate previously issued audited financial statements.
Financial Impact
No new financial data; recast of existing segment-level sales and operating income only. Consolidated net sales for 2025 were $25,116 million, net earnings $3,246 million, and diluted EPS $8.40 — all unchanged from the original filing.
Risk Factors
- None directly from this filing; the reorganization may cause temporary noise in segment-level comparisons until the new structure stabilizes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000310764-26-000041 |
| Exhibit: ex231-consentofindependent.htm | 0000310764-26-000041 |
| Document: syk-20260626.htm | 0000310764-26-000041 |
| Document: 0000310764-26-000041-index-headers.html | 0000310764-26-000041 |
| Document: 0000310764-26-000041-index.html | 0000310764-26-000041 |
| Document: 0000310764-26-000041.txt | 0000310764-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Press Release | $317.40 $275.39 | ▼ −13.24% | ▼ −13.55% | $276.20 (−12.98%) |
Aug 26, 2026 5w ago | Insider Cluster | $329.67 $274.19 | ▼ −16.83% | ▼ −18.03% | $276.20 (−16.22%) |
Aug 20, 2026 6w ago | Insider Cluster | $327.70 $280.13 | ▼ −14.52% | ▼ −14.52% | $276.20 (−15.72%) |
Jul 13, 2026 11w ago | Court Ruling | $331.45 $345.81 | ▲ +4.33% | ▲ +1.15% | $276.20 (−16.67%) |
Jul 9, 2026 12w ago | ANALYST-UPGRADE | $327.11 $337.43 | ▲ +3.15% | ▲ +0.91% | $276.20 (−15.56%) |
Jun 26, 2026 13w ago | 8-K | $332.71 $318.97 | ▼ −4.13% | ▼ −5.39% | $276.20 (−16.98%) |
Jun 17, 2026 15w ago | Court Ruling | $301.14 $331.20 | ▲ +9.98% | ▲ +8.66% | $276.20 (−8.28%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $276.20 (−7.70%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $276.20 (−7.70%) |
Apr 30, 2026 22w ago | Press Release | $293.78 $299.24 | ▼ −1.86% | ▲ +3.41% | $276.20 (+5.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access